Next Article in Journal
Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny
Previous Article in Journal
Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2010, 2(3), 313-320; doi:10.3390/pharmaceutics2030313

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease

Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
*
Author to whom correspondence should be addressed.
Received: 1 June 2010 / Revised: 26 August 2010 / Accepted: 14 September 2010 / Published: 20 September 2010
View Full-Text   |   Download PDF [232 KB, uploaded 20 September 2010]   |  

Abstract

Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function. View Full-Text
Keywords: Parkinson’s disease; amantadine; motion; cognition Parkinson’s disease; amantadine; motion; cognition
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Muhlack, S.; Müsch, P.; Konietzka, S.; Woitalla, D.; Przuntek, H.; Müller, T. Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics 2010, 2, 313-320.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top